Clinical trials: Thymic Neuroendocrine Carcinoma
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Pancreas Cancer, Ovarian Cancer
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic…
- Conditions
- Pancreas Cancer, Ovarian Cancer, Melanoma, Sarcoma
- Trial name
- RESOUND (NCT02307500)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Background: Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors
- Trial name
- NCT02146170
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)